Viewpoint

Personalising medicine will improve healthcare and create important new markets. Europe needs to move now and seize the benefits it offers, writes Richard L. Hudson.

As the Commission prepares to set out translations rules for the European patent on May 18, here are some helpful suggestions from Bruno Van Pottelsberghe of the Bruegel think tank.

EU rules on R&D funding are too onerous, MEP Jorgo Chatzimarkakis tells Science|Business’s Anna Jenkinson.

A European Court ruling on GM soy protein has implications for the patent rights of biotechs, say Nicholas Jones and Josie Zhou of the law firm Withers & Rogers LLP.

Alzheimer’s and other neurodegenerative diseases are Europe’s latest big health issue, new MEP Antonio Fernando Correia de Campos tells Science|Business.

A new ‘vision’ from Brussels offers something for everyone – including research and innovation. But in the end, it comes off as empty rhetoric.

Producing pluripotent stem cells from skin is valuable, but they can’t replace stem cells from embryos, say US scientists.

Is entrepreneurship innate, or can the requisite skills be taught? Speakers at the Science|Business ACES awards had differing views, writes Michael Kenward.

Philippe Swennen of the Association Internationale de la Mutualité tells Fabrice Delaye how insurers feel about the advent of personalised healthcare.

VCs considering an investment in a technology venture should focus more on markets if they want to mitigate risk and deliver fast returns, says Jon Treanor of Conduit Partners.